Barclays’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$537M Buy
584,100
+108,200
+23% +$110M 0.13% 120
2025
Q4
$511M Buy
475,900
+359,900
+310% +$344M 0.12% 117
2025
Q3
$88.5M Sell
116,000
-46,100
-28% -$34.3M 0.02% 547
2025
Q2
$126M Buy
162,100
+39,100
+32% +$30.4M 0.03% 397
2025
Q1
$102M Sell
123,000
-85,800
-41% -$71.4M 0.03% 413
2024
Q4
$161M Buy
208,800
+7,000
+3% +$5.8M 0.05% 273
2024
Q3
$179M Buy
+201,800
New +$181M 0.05% 277
2024
Q2
Sell
-39,100
Closed -$30.4M 5118
2024
Q1
$30.4M Sell
39,100
-6,500
-14% -$4.63M 0.01% 812
2023
Q4
$26.6M Buy
+45,600
New +$26.6M 0.01% 938
2023
Q2
Sell
-116,700
Closed -$40.1M 4837
2023
Q1
$40.1M Sell
116,700
-42,800
-27% -$14.4M 0.02% 561
2022
Q4
$58.4M Buy
+159,500
New +$56.6M 0.03% 431
2022
Q1
Sell
-97,100
Closed -$26.8M 5328
2021
Q4
$26.8M Buy
97,100
+6,800
+8% +$1.72M 0.01% 829
2021
Q3
$20.9M Buy
90,300
+36,400
+68% +$8.98M 0.01% 865
2021
Q2
$12.4M Buy
53,900
+51,800
+2,467% +$10.4M 0.01% 1110
2021
Q1
$392K Sell
2,100
-196,300
-99% -$38.4M ﹤0.01% 3327
2020
Q4
$33.5M Sell
198,400
-17,800
-8% -$2.66M 0.02% 594
2020
Q3
$32M Buy
216,200
+15,500
+8% +$2.4M 0.02% 549
2020
Q2
$33M Buy
200,700
+24,100
+14% +$3.7M 0.03% 442
2020
Q1
$24.5M Buy
176,600
+131,700
+293% +$18.1M 0.02% 558
2019
Q4
$5.9M Buy
44,900
+900
+2% +$104K ﹤0.01% 1839
2019
Q3
$4.92M Sell
44,000
-110,200
-71% -$12.3M ﹤0.01% 1868
2019
Q2
$17.1M Buy
154,200
+77,800
+102% +$9.16M 0.01% 1019
2019
Q1
$9.91M Sell
76,400
-440,300
-85% -$53.5M 0.01% 1228
2018
Q4
$59.8M Sell
516,700
-29,200
-5% -$3.26M 0.05% 322
2018
Q3
$58.6M Sell
545,900
-116,800
-18% -$11.7M 0.04% 355
2018
Q2
$56.5M Buy
662,700
+245,300
+59% +$20.1M 0.05% 325
2018
Q1
$32.3M Buy
417,400
+282,700
+210% +$22.8M 0.02% 614
2017
Q4
$11.4M Sell
134,700
-23,400
-15% -$1.99M 0.01% 1118
2017
Q3
$13.5M Sell
158,100
-32,500
-17% -$2.67M 0.01% 868
2017
Q2
$15.7M Buy
190,600
+18,100
+10% +$1.48M 0.02% 716
2017
Q1
$14.5M Sell
172,500
-452,000
-72% -$36.2M 0.02% 687
2016
Q4
$45.9M Sell
624,500
-1,173,400
-65% -$87.4M 0.05% 293
2016
Q3
$144M Buy
1,797,900
+1,669,600
+1,301% +$134M 0.16% 87
2016
Q2
$10.1M Buy
128,300
+31,200
+32% +$2.35M 0.01% 838
2016
Q1
$6.99M Sell
97,100
-32,600
-25% -$2.47M 0.01% 952
2015
Q4
$10.9M Sell
129,700
-3,000
-2% -$249K 0.01% 846
2015
Q3
$11M Buy
132,700
+56,700
+75% +$4.79M 0.01% 882
2015
Q2
$6.31M Sell
76,000
-108,200
-59% -$8.24M 0.01% 1320
2015
Q1
$13.3M Sell
184,200
-148,600
-45% -$10.6M 0.02% 916
2014
Q4
$22.6M Buy
332,800
+160,000
+93% +$10.8M 0.02% 697
2014
Q3
$11.1M Sell
172,800
-8,200
-5% -$519K 0.01% 1097
2014
Q2
$11.2M Sell
181,000
-41,500
-19% -$2.48M 0.01% 1065
2014
Q1
$12.9M Sell
222,500
-148,500
-40% -$8.29M 0.01% 967
2013
Q4
$18.9M Sell
371,000
-39,800
-10% -$1.99M 0.02% 794
2013
Q3
$20.5M Buy
410,800
+15,800
+4% +$827K 0.02% 656
2013
Q2
$19.4M Buy
+395,000
New +$21.5M 0.02% 658

Other funds holding LLY

Barclays's LLY Position: Q1 2026 in Review

Barclays increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $162M and bringing the position to 1,563,625 shares worth $1.44B. The position accounts for 0.35% of the portfolio, ranked #33.

Barclays first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.87B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Barclays held 1,563,625 shares of Eli Lilly worth $1.44B as of Q1 2026.
  • Barclays bought 159,958 Eli Lilly shares in Q1 2026, an estimated $162M.
  • Eli Lilly made up 0.35% of Barclays's portfolio in Q1 2026, its #33 holding.
  • Barclays first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Eli Lilly position peaked at $1.87B in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.